Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) overview
Familial hypercholesterolemia (FH) is a genetic disorder that affects the way the body processes cholesterol. People with FH have very high levels of low-density lipoprotein (LDL) cholesterol, also known as “bad” cholesterol, in their blood. This can lead to early and severe cardiovascular diseases, such as heart attacks and strokes. FH is caused by a mutation in one or more genes that are involved in removing LDL cholesterol from the blood. The most common gene affected is LDLR, which encodes the LDL receptor protein. Other genes that can cause FH are APOB, PCSK9, and LDLRAP1. FH is inherited in an autosomal dominant pattern, which means that having one copy of the mutated gene is enough to cause the condition. People who inherit two copies of the mutated gene have a more severe form of FH. FH affects about 1 in 250 people worldwide, but the prevalence may vary depending on the population and the genetic background. FH can be diagnosed by measuring the blood cholesterol levels, examining the physical signs of cholesterol deposits (such as xanthomas and arcus corneae), and performing genetic testing to confirm the mutation. FH can be treated with medications that lower cholesterol levels, such as statins, bile acid sequestrants, ezetimibe, and PCSK9 inhibitors. Some people with FH may also need other treatments, such as LDL apheresis or liver transplantation, to reduce their risk of complications. FH also requires lifestyle modifications, such as eating a healthy diet, exercising regularly, avoiding smoking, and managing other risk factors for cardiovascular diseases.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
